SynthesisLipids in health and disease2026
Lipoprotein(a) and adverse cardiovascular outcomes in dialysis patients: a systematic review and meta-analysis.
Synthesis in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients receiving maintenance dialysis experience exceptionally high cardiovascular morbidity and mortality. Lipoprotein(a) [Lp(a)] is an established cardiovascular risk factor in the general population; however, its prognostic significance in dialysis populations remains uncertain.
methodsA systematic review and meta-analysis of observational cohort studies evaluating circulating Lp(a) levels and adverse cardiovascular outcomes in maintenance dialysis patients were conducted. MEDLINE, Scopus, Web of Science, and CENTRAL were searched from inception through May 5, 2026. The outcomes included all-cause mortality, cardiovascular mortality, and MACEs. Random-effects meta-analysis was performed when at least two studies reported comparable adjusted hazard ratios; pooled analyses based on very few studies were considered exploratory.
resultsFifteen reports representing 14 unique cohorts and 6380 dialysis patients were included. Nine studies evaluated hemodialysis populations exclusively, three evaluated peritoneal dialysis populations, and two evaluated mixed dialysis cohorts. Exploratory meta-analyses revealed associations between elevated Lp(a) levels and all-cause mortality (HR: 1.58; 95% CI: 1.24-2.02), cardiovascular mortality (HR: 2.07; 95% CI: 1.22-3.50), and MACE (HR: 1.56; 95% CI: 1.28-1.90). Certainty was low for MACE and very low for mortality outcomes.
conclusionsAvailable evidence suggests an association between high Lp(a) concentrations and mortality and adverse cardiovascular events in maintenance dialysis patients. However, routine clinical use for cardiovascular risk stratification cannot yet be recommended because thresholds, assay standardization, incremental predictive value, and treatment implications remain unresolved.
trial registrationhttps://dx.doi.org/10.17504/protocols.io.dm6gp7491gzp/v1 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.